http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106822904-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-381 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4375 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4375 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-381 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 |
| filingDate | 2017-03-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-106822904-B |
| titleOfInvention | The pharmaceutical composition and its application of inhibitor containing AKT and IRE1 inhibitor |
| abstract | The present invention relates to the pharmaceutical compositions and its application in preparation prevention and treatment tumour medicine, the AKT inhibitor of a kind of inhibitor containing AKT and IRE1 inhibitor to be selected from MK-2206, Perifosine, Ipatasertib or AZD5363, preferably MK-2206；The IRE1 inhibitor is selected from STF-083010, APY29 or 4 μ 8C, preferably STF-083010.The pharmaceutical composition is with MK-2206 and STF-083010 drug combination, a kind of new therapeutic scheme is provided for tumor patient, growth and the cell clonal formation of tumour cell can be effectively suppressed, significant effect is better than independent medication, with addition or synergistic effect, it is low to the toxic side effect of normal cell simultaneously, it is highly-safe, it can be applied to prepare anti-tumor drug field. |
| priorityDate | 2017-03-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 52.